|A new vaccine could signal a major breakthrough in how we treat cancer.
Moderna said that its personalized cancer-vaccine program lowered the risk of death or skin-cancer recurrence in a study — a significant advance in the biotech company’s efforts to treat cancer.
Patients with melanoma who got the vaccine in combination with Merck’s cancer drug Keytruda had a 44% reduction in the rate of cancer recurrence and death, compared to those who just got Keytruda. Still, the results come from a midstage trial, and analysts say more research is needed.
Moderna famously scrambled to respond to the initial COVID-19 outbreak and developed a vaccine, which transformed the company into a drug industry powerhouse.
In an interview with Insider, Moderna’s CEO Stéphane Bancel compared the cancer study results to that moment, saying: “Now we are an oncology company.”
“The enemy now is cancer,” he added. “We know the technology works.”
Read the full story here.